RxDoctor Payments Data

Francis Magro, MD

Infectious Disease · Lowell, MANPI 1326333543

Payments from drug & device makers

$6,504in general payments, 2019–2025

Across 281 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$3K
  • AbbVie$1K
  • Viiv Healthcare Company$849
  • Merck$658
  • Johnson & Johnson$342
  • Pfizer$161
  • plus $371 from 10 others

What the payments were for

  • Food & beverage$6,504100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,504 in reported general payments places this provider in the 70th percentile of 368 infectious disease providers in Massachusetts.

See all infectious disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$62,874
Medicare patients
266
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala33$173,288
TriumeqAbacavir/Dolutegravir/Lamivudi22$87,693
DescovyEmtricitabine/Tenofov Alafenam12$25,376
ErtapenemErtapenem Sodium42$13,944
Moxifloxacin Hcl30$2,858
Rifampin45$2,158
Ethambutol Hcl23$1,288
Methenamine Hippurate16$1,230
Penicillin V Potassium35$894
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav15$518
CeftriaxoneCeftriaxone Sodium21$418
Isoniazid32$238
Cephalexin28$236
Azithromycin16$227
Ciprofloxacin Hcl12$142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$2,683$198,66445 claims
Viiv Healthcare CompanyTriumeq$849$87,69322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 368 infectious disease providers in Massachusetts.

Other infectious disease in Lowell

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →